Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$2.90 USD
+0.05 (1.75%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRVI 2.90 +0.05(1.75%)
Will TRVI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRVI
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
TRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for TRVI
Trevi Therapeutics management to meet with Oppenheimer
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Trevi Therapeutics initiated with bullish view at Rodman & Renshaw
12 Health Care Stocks Moving In Thursday's After-Market Session
Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript